These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10425097)

  • 41. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
    Dobbin PS; Hider RC; Hall AD; Taylor PD; Sarpong P; Porter JB; Xiao G; van der Helm D
    J Med Chem; 1993 Aug; 36(17):2448-58. PubMed ID: 8355246
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polyamine-vectored iron chelators: the role of charge.
    Bergeron RJ; Bharti N; Wiegand J; McManis JS; Yao H; Prokai L
    J Med Chem; 2005 Jun; 48(12):4120-37. PubMed ID: 15943485
    [TBL] [Abstract][Full Text] [Related]  

  • 43. (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
    Bergeron RJ; Wiegand J; McManis JS; Vinson JR; Yao H; Bharti N; Rocca JR
    J Med Chem; 2006 May; 49(9):2772-83. PubMed ID: 16640338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug evaluation: Deferitrin for iron overload disorders.
    Barton JC
    IDrugs; 2007 Jul; 10(7):480-90. PubMed ID: 17642018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Iron chelators: in vitro inhibitory effect on the liver stage of rodent and human malaria.
    Stahel E; Mazier D; Guillouzo A; Miltgen F; Landau I; Mellouk S; Beaudoin RL; Langlois P; Gentilini M
    Am J Trop Med Hyg; 1988 Sep; 39(3):236-40. PubMed ID: 3052118
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic.
    Baker E; Wong A; Peter H; Jacobs A
    Br J Haematol; 1992 Jul; 81(3):424-31. PubMed ID: 1340769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolically programmed iron chelators.
    Bergeron RJ; Bharti N; McManis JS; Wiegand J
    Bioorg Med Chem; 2015 Sep; 23(17):5954-71. PubMed ID: 26231739
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of desferrithiocin, an oral iron chelator, on T-cell function.
    Bierer BE; Nathan DG
    Blood; 1990 Nov; 76(10):2052-9. PubMed ID: 2242426
    [TBL] [Abstract][Full Text] [Related]  

  • 49. N-phthaloyl-glycine-hydroxamic acid as serum iron chelator in rats.
    Matijević-Sosa J; Samarzija I; Honović L; Jurisić B
    Acta Pharm; 2008 Jun; 58(2):231-6. PubMed ID: 18515233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytoprotection and iron mobilization in rat hepatocyte cultures by a new synthetic dihydroxamate chelator.
    Rakba N; Nguyen-Van-Duong MK; Nicolas L; Guillot V; Morel I; Pasdeloup N; Brissot P; Lescoat G
    Toxicol Lett; 1999 Oct; 110(1-2):19-27. PubMed ID: 10593591
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Significance of asymmetric sites in choosing siderophores as deferration agents.
    Bergeron RJ; Xin MG; Weimar WR; Smith RE; Wiegand J
    J Med Chem; 2001 Jul; 44(15):2469-78. PubMed ID: 11448229
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and biological properties of iron chelators based on a bis-2-(2-hydroxy-phenyl)-thiazole-4-carboxamide or -thiocarboxamide (BHPTC) scaffold.
    Rodriguez-Lucena D; Gaboriau F; Rivault F; Schalk IJ; Lescoat G; Mislin GL
    Bioorg Med Chem; 2010 Jan; 18(2):689-95. PubMed ID: 20036563
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
    Liu J; Obando D; Schipanski LG; Groebler LK; Witting PK; Kalinowski DS; Richardson DR; Codd R
    J Med Chem; 2010 Feb; 53(3):1370-82. PubMed ID: 20041672
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hydroxamic acid-containing hydrogels for nonabsorbed iron chelation therapy: synthesis, characterization, and biological evaluation.
    Polomoscanik SC; Cannon CP; Neenan TX; Holmes-Farley SR; Mandeville WH; Dhal PK
    Biomacromolecules; 2005; 6(6):2946-53. PubMed ID: 16283713
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The development of new iron-chelating drugs. II.
    Grady RW; Graziano JH; White GP; Jacobs A; Cerami A
    J Pharmacol Exp Ther; 1978 Jun; 205(3):575-65. PubMed ID: 660531
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of acetic acid-induced colitis by desferrithiocin analogs in a rat model.
    Bergeron RJ; Wiegand J; Weimar WR; Nguyen JN; Sninsky CA
    Dig Dis Sci; 2003 Feb; 48(2):399-407. PubMed ID: 12643622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular structure and biological and pharmacological properties of 3-hydroxy-2-methyl-1-(beta-D-ribofuranosyl or pyranosyl)-4-pyridinone: potential iron overload drugs for oral administration.
    Liu G; Bruenger FW; Miller SC; Arif AM
    Bioorg Med Chem Lett; 1998 Nov; 8(21):3077-80. PubMed ID: 9873679
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Investigation into Iron Chelating and Antioxidant Potential of Melilotus officinalis in Iron Dextran Induced Iron Overloaded Sprague Dawley Rat Model.
    Sheikh NA; Desai TR; Tirgar PR
    Drug Res (Stuttg); 2016 Dec; 66(12):618-627. PubMed ID: 27626608
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Deferitazole, a new orally active iron chelator.
    Hider RC; Kong X; Abbate V; Harland R; Conlon K; Luker T
    Dalton Trans; 2015 Mar; 44(11):5197-204. PubMed ID: 25687725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antioxidant activity and cellular uptake of the hydroxamate-based fungal iron chelators pyridoxatin, desferriastechrome and desferricoprogen.
    da Silva GS; Shang Z; Kalansuriya P; Capon RJ; Espósito BP
    Biometals; 2019 Aug; 32(4):707-715. PubMed ID: 31152280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.